Safety of the drug
 

(Photos: Internet)
Drug Administration: Provides information regarding the safety of gadolinium-containing contrast agents; Codeine, tramadol; Hyoscine butylbromide; risperidone; Medium contains chlorhexidine gluconate
On May 19, 1977, the Advisory Council granted drug registration numbers - The Ministry of Health has agreed to update information on the safety of some drugs, specifically as follows:
1. Containing gadolinium-containing contrast medium:
The European Pharmacovigilance (PREC) Pharmacovigilance (PRAC) Commission has found convincing evidence of the accumulation of gadolinium in the patient's brain after months of drug use. The accumulation of gadolinium in tissues and in other organs is associated with rare side effects such as skin rash and nephrogenic systemic fibrosis - a serious disease that occurs in patients with renal failure.
Medications containing codeine for cough and pain relief, drugs containing tramadol active ingredient:

The US Food and Drug Administration (FDA) has announced limits on the use of codeine and tramadol in children. These drugs have serious risks, including: slow breathing, difficulty breathing and death. These risks are more serious in children under 12 years of age. The FDA is seeking to change the label of all prescription drug products that contain the ingredients listed above. Specific FDA requirements are as follows:
            - Codeine is not used to treat pain and cough. Tramadol is not used to treat pain in children under 12 years of age.
            Contraindicated use of tramadol in children under 18 years of age for pain relief following amiodarone shaving and / or curettage. (For Codeine, FDA has requested this supplemental contraceptive from February 2013).
- Warning against the use of codeine and tramadol for adolescents aged 12 to 18 who are obese or have conditions such as obstructive sleep apnea or severe lung disease, which are risk factors. Muscle of severe respiratory problems.
- Warn mothers not to breastfeed while being treated with codeine or tramadol because of the risk of severe adverse reactions that may be experienced in breastfed infants. These adverse reactions include: sluggishness, heavy sleep, difficulty feeding or severe respiratory problems, even death.
3. The drug contains the active ingredient hyoscine butylbromide:
                                   
The UK Health and Medical Product Administration (MHRA) has warned of the potential serious adverse effects of hyoscine butylbromide in patients with heart disease. At the same time MHRA also recommends health workers as follows:
- Hyoscine butylbromide injections can cause serious adverse effects, including: tachycardia, hypotension and anaphylactic reaction. These adverse effects can lead to death in patients with heart disease such as heart failure, coronary heart disease, arrhythmias or hypertension.
Hyoscine butylbromide injection should be used with caution in patients with heart disease. Close monitoring of these patients should be undertaken and the means as well as emergency personnel ready as needed.
Hyoscine butylbromide is still contraindicated in patients with tachycardia.
Medicines containing risperindone:
Singapore Health Authority (HAS) has announced the indicative limit for risperidone in the treatment of dementia due to cerebrovascular events such as stroke, transient ischemic attack including death death To minimize this risk, HAS recommends that risperidone be prescribed only for short-term treatment in patients with moderate to severe Alzheimer's dementia who do not respond to non-drug therapy.
5. Skin cleansers containing chlorhexidine gluconate:
The US Food and Drug Administration (FDA) warns of rare but severe allergic reactions (wheezing or difficulty breathing, facial swelling, and urticaria, and may progress rapidly to severe symptoms. more severe such as severe rash or shock) have been reported in relation to commonly used skin cleansers containing chlorhexidine gluconate.